Find information on thousands of medical conditions and prescription drugs.

Melagatran

Ximelagatran (Exanta® or Exarta®, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved. more...

Home

Marinol

Marplan

Matulane

Maxair

Maxalt

Maxolon

MDMA

Medrol

Mobic

Modicon

Motrin

Mucinex

Muse

Mykacet

Mykinac

Myleran

Mylotarg

Mysoline

Phentermine

Method of action

Ximelagatran was the first member of the drug class of direct thrombin inhibitors that can be taken orally. It acts solely by inhibiting the actions of thrombin. It is taken orally twice daily, and rapidly absorbed by the small intestine. Ximelagatran is a prodrug, being converted in vivo to the active agent melagatran. This conversion takes place in the liver and many other tissues through dealkylation and dehydroxylation (replacing the ethyl and hydroxyl groups with hydrogen).

Uses

Ximelagatran was expected to replace warfarin and sometimes aspirin and heparin in many therapeutic settings, including deep venous thrombosis, prevention of secondary venous thromboembolism and atrial fibrillation. The efficacy of ximelagatran for these indications had been well-documented (Eriksson et al 2003, Frances et al 2004, Schulman et al 2004).

An advantage, according to early reports by its manufacturer, was that it could be taken orally without any monitoring of its anticoagulant properties. This would have set it apart from warfarin and heparin, which require monitoring of the international normalized ratio (INR) and the partial thromboplastin time (PTT), respectively. A disadvantage recognised early was the absence of an antidote in case acute bleeding develops, while warfarin can be antagonised by vitamin K and heparin by protamine sulfate.

Side-effects

Ximelagatran was generally well tolerated in the trial populations, but a small proportion (5-6%) developed elevated liver enzyme levels, which prompted the FDA to reject an initial application for approval in 2004. The further development was discontinued in 2006 after it turned out hepatic damage could develop in the period subsequent to withdrawal of the drug. According to AstraZeneca, a chemically different but pharmacologically similar substance, AZD0837, is undergoing testing for similar indications.

Read more at Wikipedia.org

• [List your site here Free!]

Research and Markets: The Cardiovascular Market Outlook to 2008:
From Business Wire, 4/28/04

Business Editors

DUBLIN, Ireland--(BUSINESS WIRE)--April 28, 2004

Research and Markets (http://www.researchandmarkets.com) has announced the addition of The Cardiovascular Market Outlook to 2008 to their offering.

The Cardiovascular Market Outlook to 2008, is a comprehensive source of market analysis of the most valuable therapy area within the global pharmaceutical market Valued at an estimated $73.7bn in 2002, the global market for cardiovascular drugs grew by a moderate 2.5% over 2001 levels.

But how much do you know about the fastest growing cardiovascular (CV) segment? Who has the fastest growing CV portfolio? And how will the market develop in the next five years? All these questions and more are answered in this management report. This report provides detailed analysis of patient pool potential, sub-markets, leading companies' strategies, key industry developments and potential CV blockbusters of the future.

With this analysis you will be able to identify areas for investment and develop strategies to counter any upcoming threats to your CV drug portfolio. Lifecycle management strategies are also becoming as important as product innovation in maintaining and building market shares and revenues. Understand how leading companies are maximizing lifecycle management strategies to extend revenue streams within the cardiovascular market with this new report.

Top five reasons to buy this report

- Analyze the recent performance of drugs in each therapeutic class of the global cardiovascular market.

- Understand how the competitive landscape may be changed by the results of clinical trials such as CURE, LIFE, ALLHAT and HOPE.

- Assess the strength of leading players' cardiovascular portfolios and identify how they are positioning themselves to maintain and build franchise revenues.

- Quantify your products' market potential in the cardiovascular market by evaluating the patient base in different therapeutic classes.

- Benchmark the performance and potential of future cardiovascular blockbuster drugs from compounds currently in development, including third generation statins, new anti-hypertensives and an oral anti-coagulant.

Leading players in the cardiovascular market

Summary

Introduction

Global market shares

Pfizer

Marketed products

R&D compounds